药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
3,7,11,15-tetramethyl-hexadecan-1-ol
Risankizumab
The risk or severity of adverse effects can be increased when Risankizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Emapalumab
The risk or severity of adverse effects can be increased when Emapalumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Cemiplimab
The risk or severity of adverse effects can be increased when Cemiplimab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Lanadelumab
The risk or severity of adverse effects can be increased when Lanadelumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Lecanemab
The risk or severity of adverse effects can be increased when Lecanemab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Fanolesomab
The risk or severity of adverse effects can be increased when Fanolesomab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Galcanezumab
The risk or severity of adverse effects can be increased when Galcanezumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Fremanezumab
The risk or severity of adverse effects can be increased when Fremanezumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Eptinezumab
The risk or severity of adverse effects can be increased when Eptinezumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Erenumab
The risk or severity of adverse effects can be increased when Erenumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Burosumab
The risk or severity of adverse effects can be increased when Burosumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Tildrakizumab
The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Besilesomab
The risk or severity of adverse effects can be increased when Besilesomab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Sulesomab
The risk or severity of adverse effects can be increased when Sulesomab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Emicizumab
The risk or severity of adverse effects can be increased when Emicizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Human cytomegalovirus immune globulin
The risk or severity of adverse effects can be increased when Human cytomegalovirus immune globulin is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Nebacumab
The risk or severity of adverse effects can be increased when Nebacumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Edrecolomab
The risk or severity of adverse effects can be increased when Edrecolomab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Bezlotoxumab
The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Olokizumab
The risk or severity of adverse effects can be increased when Olokizumab is combined with Belantamab mafodotin.